Filana Therapeutics, Inc.
(FLNA)Financial Statements · SEC EDGAR XBRL
Net Income
-$91.0M
-273.7%
EPS
$-1.88
-28.8%
Op. Income
-$95.4M
+32.6%
FCF
-$32.8M
+71.9%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Operating Expenses & Income
Research & Development
Total Operating Expenses
Operating Income
Non-Operating Income/Expense
Other Non-Operating Income
Income Tax Expense
Net Income
EPS (Basic)
EPS (Diluted)